Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11733765 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL8097012 | 0.80 | POLB (0.77) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL18600723 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL11874002 | 0.77 | CXCR1 (0.68) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL4971640 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL915213 | 0.77 | MEN1 (0.64) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL2243374 | 0.77 | MAPT (0.72) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL17149399 | 0.77 | GAA (0.66) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL11859468 | 0.75 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 | |
| SCHEMBL1024222 | 0.75 | CXCR2 (0.68) | SMN1; SMN2LMNAHTTALDH1A1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390343-B1 | NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-7166744-B2 | Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2007-01-23 | — | — | US | disclosed |
| CN-1269799-C | Novel retinoid derivatives, process for producing the same and anti-cancer pharmaceutical composition comprising the same | CHEBIGEN CO LTD (KR) | 2006-08-16 | — | — | CN | disclosed |
| EP-1390343-A4 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1390343-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | Chebigen Co., Ltd. (KR) | 2004-02-25 | — | — | EP | disclosed |
| CN-1455765-A | Novel retinoid derivatives and production method thereof and anti-cancer pharmaceutical composition comprising same | CHEBIGEN CO LTD (KR) | 2003-11-12 | — | — | CN | disclosed |
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| WO-2002096857-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | RXRB, RARB, RXRA | SMN1; SMN2 4240/4885LMNA 2056/4885HTT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.